Celsion Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Celsion stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLSN, but not buy additional shares or sell existing shares.
View analyst ratings for Celsion or view top-rated stocks.

Wall Street analysts have given Celsion a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Celsion wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Celsion saw a increase in short interest during the month of February. As of February 26th, there was short interest totaling 3,710,000 shares, an increase of 78.4% from the February 11th total of 2,080,000 shares. Based on an average daily volume of 18,460,000 shares, the short-interest ratio is currently 0.2 days. Currently, 6.2% of the company's shares are short sold.
View Celsion's Short Interest.

Celsion is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Celsion.

Celsion Co. (NASDAQ:CLSN) issued its earnings results on Thursday, March, 18th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.08. Celsion had a negative net margin of 4,315.00% and a negative trailing twelve-month return on equity of 104.32%.
View Celsion's earnings history.

Celsion's stock was trading at $0.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLSN shares have increased by 28.8% and is now trading at $1.2750.
View which stocks have been most impacted by COVID-19.

Shares of Celsion reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

2 Wall Street analysts have issued 1-year target prices for Celsion's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Celsion's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 213.7% from the stock's current price.
View analysts' price targets for Celsion or view top-rated stocks among Wall Street analysts.

Some companies that are related to Celsion include Homology Medicines (FIXX), CorMedix (CRMD), BELLUS Health (BLU), Tonix Pharmaceuticals (TNXP), BioDelivery Sciences International (BDSI), Cue Biopharma (CUE), Aeglea BioTherapeutics (AGLE), Oncorus (ONCR), Verrica Pharmaceuticals (VRCA), Oncternal Therapeutics (ONCT), RedHill Biopharma (RDHL), Frequency Therapeutics (FREQ), Hookipa Pharma (HOOK), Orphazyme A/S (ORPH) and Ampio Pharmaceuticals (AMPE).
View all of CLSN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Agenus (AGEN) and CBL & Associates Properties (CBL).

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLSN stock can currently be purchased for approximately $1.28.

Celsion has a market capitalization of $95.65 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

Celsion employs 29 workers across the globe.

The official website for Celsion is www.celsion.com.

Celsion is headquartered at 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at (609) 896-9100 or via email at [email protected]